Aili L. Zhang

No. 12 Jian Kang Road, 
Shijiazhuang, CN 
No. 12 Jian Kang Road, 
Shijiazhuang, CN 

Overview

Aili Zhang practices practicing medicine in Shijiazhuang, China.

Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Prostate Cancer, and Familial Prostate Cancer.

She is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

No. 12 Jian Kang Road, Shijiazhuang, 050011, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3

26 Total Publications

Overexpression of the MAPK transcription factor gene MSS11 enhances ethanol biosynthesis in Saccharomyces cerevisiae via coordinated metabolic and stress-response reprogramming.
Overexpression of the MAPK transcription factor gene MSS11 enhances ethanol biosynthesis in Saccharomyces cerevisiae via coordinated metabolic and stress-response reprogramming.
Journal: FEMS yeast research
Published: January 13, 2026

Frequently Asked Questions about Aili L. Zhang

Is Aili L. Zhang a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Aili L. Zhang is classified as an Experienced expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Aili L. Zhang participate in research or clinical trials?

Yes. Aili L. Zhang has published 26 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Aili L. Zhang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Zhang's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile